Wealthquest Corp reduced its stake in Eli Lilly And Co (NYSE:LLY) by 3.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,081 shares of the company’s stock after selling 226 shares during the period. Wealthquest Corp’s holdings in Eli Lilly And Co were worth $673,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of LLY. Norges Bank bought a new position in Eli Lilly And Co in the 4th quarter worth about $1,056,086,000. Thoroughbred Financial Services LLC grew its stake in Eli Lilly And Co by 11,124.4% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 854,403 shares of the company’s stock worth $85,440,000 after acquiring an additional 846,791 shares in the last quarter. Geode Capital Management LLC grew its stake in Eli Lilly And Co by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock worth $1,514,582,000 after acquiring an additional 830,689 shares in the last quarter. Bessemer Group Inc. grew its stake in Eli Lilly And Co by 2,354.5% in the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock worth $63,096,000 after acquiring an additional 546,307 shares in the last quarter. Finally, Goelzer Investment Management Inc. grew its stake in Eli Lilly And Co by 1,345.5% in the 1st quarter. Goelzer Investment Management Inc. now owns 312,151 shares of the company’s stock worth $40,505,000 after acquiring an additional 290,557 shares in the last quarter. Institutional investors and hedge funds own 79.50% of the company’s stock.
NYSE:LLY traded up $0.77 during midday trading on Thursday, reaching $109.72. 2,175,129 shares of the stock traded hands, compared to its average volume of 3,627,093. Eli Lilly And Co has a 12-month low of $97.53 and a 12-month high of $132.13. The firm has a 50-day moving average price of $111.16. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. The company has a market cap of $105.55 billion, a PE ratio of 19.77, a PEG ratio of 1.93 and a beta of 0.20.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $0.645 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.35%. Eli Lilly And Co’s payout ratio is 46.49%.
In related news, CFO Joshua L. Smiley purchased 426 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were acquired at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the purchase, the chief financial officer now owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christi Shaw sold 7,577 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $117.14, for a total transaction of $887,569.78. Following the transaction, the senior vice president now owns 500 shares in the company, valued at approximately $58,570. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
A number of brokerages have commented on LLY. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. BMO Capital Markets upped their price target on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $143.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Finally, TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $123.49.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.